Multi-omics view of androgenetic alopecia in scalp tissue

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will collect scalp tissue from healthy controls and men with Hamilton-Norwood Stage III AGA, then apply single-cell RNA sequencing and spatial transcriptomics to map cell types and spatial relationships. The goal is to identify key cell subpopulations and disease-associated targets, with functional validation in patient-derived organoids and animal models. The study aims to reveal mechanisms of hair follicle stem cell exhaustion and uncover potential therapeutic targets. Data from the study may inform future interventions for AGA by highlighting critical cellular networks and molecular pathways.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age and Gender: Males aged 25-30 or 60-65 years.
* Diagnosis: Patient Group: Diagnosed by a physician with Hamilton-Norwood Stage III androgenetic alopecia (AGA). Healthy Control Group: Healthy scalp with no signs of hair loss.
* Medication and Treatment History: No use of anti-hair loss medications (e.g., minoxidil, finasteride), hormonal drugs, or scalp chemical treatments (perm or dye) within the last 6 months.
* Informed Consent: Voluntarily signed and provided written informed consent.

Exclusion Criteria:

* Scalp Conditions: Presence of other types of alopecia (besides AGA) or active scalp diseases (e.g., psoriasis, dermatitis, infections).
* Medical History: History of keloids or coagulation disorders.
* Systemic Diseases: Major underlying conditions, including severe cardiovascular/cerebrovascular diseases, immune system disorders, or malignant tumors.
* Allergies: Known hypersensitivity to local anesthetics.
* Prior Clinical Trials: Participation in any other clinical trials within 3 months prior to screening.
* Other Factors: Any other conditions deemed unsuitable for participation by the investigator.

Where it's running

• The First Affiliated Hospiatl of Henan Medical University
  Xinxiang, Henan, China Recruiting

Study contacts

• Study coordinator: Wenjie Ren
• Email: 157121431@qq.com
• Phone: 8618937302619

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Exosome therapy for male pattern baldness

  This trial tests whether injecting hUCMSC-derived exosomes into the scalp can promote hair regrowth in men with androgenetic alopecia, compared with a placebo.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07693244

• VENEZE peptide hair serum versus 2% topical minoxidil for androgenetic alopecia

  This trial tests if VENEZE peptide hair serum helps adults with androgenetic alopecia grow thicker, denser hair compared with 2% topical minoxidil.

  Recruiting at 2 sites Institute of Dermatology, Thailand · Bangkok, Bangkok and 1 other locations · NCT07536100

• Topical Lactobacillus reuteri for hair loss due to androgenetic alopecia

  This trial will test whether applying a topical Lactobacillus reuteri solution can increase hair count and improve hair quality in adults (18–60) with androgenetic alopecia over 12 months.

  Recruiting Phase 2 Shenzhen People's Hospital · Shenzhen, Guangdong · NCT07370519

• OLX72021 for men with male-pattern hair loss

  This research will test whether OLX72021 is safe and may help men aged 18 to 59 with mild to moderate male-pattern hair loss.

  Recruiting Phase 1/2 Olix Pharmaceuticals, Inc. · Botany, New South Wales and 7 other locations · NCT07327359

• ABS-201 for improving hair growth in healthy adults and people with androgenetic alopecia

  This trial will test whether ABS-201 is safe and helps hair grow in healthy adults and in men and women with androgenetic alopecia.

  Recruiting at 5 sites Phase 1/2 Absci Pty Ltd. · Sydney, New South Wales and 4 other locations · NCT07317544

• Thulium laser with growth-factor serum (with or without LED) for androgenetic hair loss

  This trial tests whether thulium laser plus a growth-factor serum, with or without added LED light, can improve hair growth in adults with androgenetic alopecia.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg, Free and Hanseatic City of Hamburg · NCT07079657

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.